# Salt-Sensitivity and Immunity Cell Activation

> **NCT03753204** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Vanderbilt University Medical Center** · enrollment: 20 (estimated)

## Conditions studied

- High Blood Pressure
- Salt; Excess
- Inflammation

## Interventions

- **DRUG:** Furosemide 40 mg

## Key facts

- **NCT ID:** NCT03753204
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-01
- **Primary completion:** 2026-09-01
- **Final completion:** 2026-09-15
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03753204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03753204, "Salt-Sensitivity and Immunity Cell Activation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03753204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*